This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Greiner R-A, Braathen LR.Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. 5th International Congress on Psoriasis: From Gene to Clinic: 1427 abstr. P68, 4 Dec 2008. Available from: URL: http://www.psoriasisg2c.org.uk
Rights and permissions
About this article
Cite this article
Infliximab good value for money in psoriasis. Pharmacoecon. Outcomes News 570, 6 (2009). https://doi.org/10.2165/00151234-200905700-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905700-00017